Understanding Affordability Options

Understanding Affordability Options

Sometimes we all need a little help from our friends

Janssen CarePath provides a wealth of information for healthcare providers and their patients. Share these brochures with your patients to learn more about health plan open enrollment and affordability options.

Health Plan Open Enrollment Brochure

Even if patients keep the same health plan, benefits can change. The information in the Open Enrollment brochure can help patients review their health plan coverage and make changes if needed so they can stay on treatment in the new benefit period.

Affordability Options Overview

In recent years healthcare choices have expanded significantly, many due to advances in pharmaceutical treatments. Although prescription drug expense represents only a small portion of total U.S. healthcare spending, the out-of-pocket costs for individual patients can be significant. This tool highlights some of the resources that are available to assist patients with their prescription drug costs and correlates the options with primary insurance status.

Medicare Resource Guide

Our Medicare Resource Guide provides important information for your patients to consider as they select their insurance coverage.

Medicare Low-Income Subsidy Guide

This guide can help patients understand how the Medicare Part D Low-Income Subsidy (LIS) program may be able to help them afford the out-of-pocket costs usually associated with Medicare Part D Prescription Drug Plans (PDPs).

Indication

TREMFYA™ is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA™ is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA™ is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA™ after physician approval and proper training.

Important Safety Information For TREMFYA

Important Safety Information

Infections
TREMFYA™ may increase the risk of infection. Treatment with TREMFYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA™ until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA™. Initiate treatment of latent TB prior to administering TREMFYA™. Monitor patients for signs and symptoms of active TB during and after TREMFYA™ treatment. Do not administer TREMFYA™ to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA™.

Adverse Reactions
Most common (≥1%) adverse reactions associated with TREMFYA™ include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA™.  Provide the Medication Guide to your patients and encourage discussion.

067010-170208